Spero Therapeutics Inc at Ladenburg Thalmann Virtual Healthcare Conference Transcript
All right. Welcome, everyone. My name is Michael Higgins, Managing Director, Senior Biotech Analyst here at Ladenburg Thalmann. On behalf of the company, I want to thank you for joining us at our conference -- our virtual conference here this year. Long list of companies to present, so I'm going to step out of the way here.
The next company up is Spero Therapeutics. And to present for the Company is CEO, Ankit Mahadevia. Ankit, take it away and thanks for joining us.
Well, thank you, Michael, and to your Ladenburg colleagues for the opportunity to share the story. It will be great to review our progress. So I'll skirt past some of the forward-looking statements and dive into the story.
And Spero's vision was to be built from the ground up as a leader in infectious disease therapy. I think we've all experienced together, for the last 15 months or so, how infections can change both the course of patient care, but also
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |